<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23842" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Kaposi Sarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bishop</surname>
            <given-names>Bradie N.</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lynch</surname>
            <given-names>David T.</given-names>
          </name>
          <aff>SAMMC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bradie Bishop declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Lynch declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23842.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Kaposi sarcoma is an interesting soft tissue tumor occurring in several distinct populations with a variety of presentations and courses. In its most well-known form, Kaposi sarcoma occurs in patients with immunosuppression, such as those with acquired immunodeficiency syndrome (AIDs) or those undergoing immunosuppression due to an organ transplant. This activity reviews the cause, presentation and pathophysiology of kaposi sarcoma and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the epidemiology of kaposi sarcoma.</p></list-item><list-item><p>Review the presentation of kaposi sarcoma.</p></list-item><list-item><p>Summarize the treatment options for kaposi sarcoma.</p></list-item><list-item><p>Explain modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by kaposi sarcoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23842&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23842">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23842.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Kaposi sarcoma is an interesting soft tissue tumor occurring in several distinct populations with a variety of presentations and courses. In its most well-known form, Kaposi sarcoma occurs in patients with immunosuppression, such as those with acquired immunodeficiency syndrome (AIDs) or those undergoing immunosuppression due to an organ transplant. Initially described in 1872 by Moritz Kaposi, an Austro-Hungarian dermatologist in 5 patients with the multifocal disease,<xref ref-type="bibr" rid="article-23842.r1">[1]</xref>&#x000a0;human herpesvirus/Kaposi sarcoma herpesvirus (HHV-8) was discovered as a causative agent of Kaposi sarcoma as the AIDS epidemic progressed in the 1980s.<xref ref-type="bibr" rid="article-23842.r2">[2]</xref>&#x000a0;Four clinical forms emerged.</p>
        <list list-type="order">
          <list-item>
            <p>Classic form occurring in elderly men of Mediterranean and Eastern European descent on the lower extremities</p>
          </list-item>
          <list-item>
            <p>Endemic African form with generalized lymph node involvement occurring in children</p>
          </list-item>
          <list-item>
            <p>HIV-related form occurring with patients not taking highly active antiretroviral therapy (HAART) with diffuse involvement of the skin and internal organs</p>
          </list-item>
          <list-item>
            <p>Iatrogenic form in immunosuppressed patients also with diffuse involvement of the skin and internal organs</p>
          </list-item>
        </list>
        <p>Each form has a differing natural history ranging from indolent to more aggressive and fatal in anaplastic varieties.<xref ref-type="bibr" rid="article-23842.r3">[3]</xref></p>
      </sec>
      <sec id="article-23842.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Human herpesvirus-8 (HHV-8) is present in all forms of Kaposi sarcoma.<xref ref-type="bibr" rid="article-23842.r4">[4]</xref>&#x000a0;HHV-8 interferes with many normal cell functions and requires cofactors like cytokines or specific proteins to result in the development of Kaposi sarcoma.<xref ref-type="bibr" rid="article-23842.r5">[5]</xref>&#x000a0;Other malignancies associated with HHV-8 include plasmablastic multicentric Castleman disease, primary effusion lymphoma, intravascular large B cell lymphoma, and occasionally angiosarcoma and inflammatory myofibroblastic tumor.<xref ref-type="bibr" rid="article-23842.r5">[5]</xref></p>
      </sec>
      <sec id="article-23842.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Classic Kaposi sarcoma has a male: female ratio 17:1 and occurs primarily in patients over 50 years old of Eastern European and Mediterranean descent. These patients are at greater risk for secondary malignancies.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref><xref ref-type="bibr" rid="article-23842.r7">[7]</xref>&#x000a0; The prevalence mirrors the distribution of HHV-8 throughout the world.<xref ref-type="bibr" rid="article-23842.r8">[8]</xref>&#x000a0;Within the United States, incidence has been stable around 1:100,000 since 1997.<xref ref-type="bibr" rid="article-23842.r9">[9]</xref></p>
        <p>Endemic Kaposi sarcoma has the unusual predilection for the pediatric population and mirrors HHV-8 seropositivity.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref>&#x000a0;The rates of seropositivity in pediatric patients vary extensively throughout Africa, from a low of 2% in Eritrea to almost 100% in the Central African Republic.<xref ref-type="bibr" rid="article-23842.r10">[10]</xref>&#x000a0;Following the HIV epidemic in Africa, the ratio of men to women with Kaposi sarcoma has fallen from 7:1 to 2:1.<xref ref-type="bibr" rid="article-23842.r11">[11]</xref>&#x000a0;Endemic Kaposi sarcoma is now the most common cancer in men and the second most common cancer in women with Uganda and Zimbabwe.<xref ref-type="bibr" rid="article-23842.r11">[11]</xref></p>
        <p>HHV-8 seropositivity worldwide varies, with a high of 40% in Saharan Africa to 2% to 4% in Northern Europe, Southeast Asia, and Caribbean countries. Approximately 10% of Mediterranean countries and 5-20% of United States patients are seropositive for HHV-8.<xref ref-type="bibr" rid="article-23842.r12">[12]</xref><xref ref-type="bibr" rid="article-23842.r13">[13]</xref>&#x000a0;This unique predilection for sub-Saharan African, the Mediterranean, and South America is unique to HHV-8 amongst human herpesviruses.<xref ref-type="bibr" rid="article-23842.r14">[14]</xref></p>
        <p>AIDS-related Kaposi sarcoma is the second most common tumor in HIV patients with CD4 counts less than 200 cells/mm3 and is an AIDs-defining illness.<xref ref-type="bibr" rid="article-23842.r15">[15]</xref>&#x000a0;Up to 30% of HIV patients not taking high-activity antiretroviral therapy (HAART) will develop Kaposi sarcoma. HIV positive male homosexuals have a 5- to 10-fold increased the risk of Kaposi sarcoma.<xref ref-type="bibr" rid="article-23842.r16">[16]</xref><xref ref-type="bibr" rid="article-23842.r6">[6]</xref></p>
        <p>Iatrogenic Kaposi sarcoma has a male: female ratio of 3:1 <xref ref-type="bibr" rid="article-23842.r6">[6]</xref>. Over 5% of transplant patients who develop a de novo malignancy will develop Kaposi sarcoma, a 400- to 500-fold increased risk over the general population.<xref ref-type="bibr" rid="article-23842.r17">[17]</xref><xref ref-type="bibr" rid="article-23842.r18">[18]</xref>&#x000a0;Patients with bone marrow or peripheral blood stem cell transplant have much lower risks of developing Kaposi sarcoma compared to solid organ transplant patients.<xref ref-type="bibr" rid="article-23842.r18">[18]</xref><xref ref-type="bibr" rid="article-23842.r6">[6]</xref></p>
      </sec>
      <sec id="article-23842.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>HHV-8 is a double-stranded enveloped DNA virus with 6 major subtypes (A-F).<xref ref-type="bibr" rid="article-23842.r9">[9]</xref></p>
        <p>Due to HHV-8 co-evolving with the human population for centuries, cofactors of immune defects and inflammation are required for the development of malignancy.<xref ref-type="bibr" rid="article-23842.r14">[14]</xref>&#x000a0;It is transmitted primarily via saliva in childhood and sexually, with some cases of infection via blood transfusion or intravenous drug use.<xref ref-type="bibr" rid="article-23842.r14">[14]</xref>&#x000a0;Seropositive family members will often infect other family members, particularly in areas where HHV-8 is endemic.<xref ref-type="bibr" rid="article-23842.r14">[14]</xref><xref ref-type="bibr" rid="article-23842.r6">[6]</xref></p>
        <p>After infecting endothelial cells, HHV-8 activates the mTOR pathway, alters the cells to have mesenchymal differentiation, and promotes aberrant angiogenesis <xref ref-type="bibr" rid="article-23842.r14">[14]</xref>. Through immune suppression and inflammation, the HHV-8 infected cells can persist and proliferate. Expression of latency-associated nuclear antigen (LANA) causes binding of p53 and suppression of apoptosis <xref ref-type="bibr" rid="article-23842.r14">[14]</xref><xref ref-type="bibr" rid="article-23842.r19">[19]</xref>. LANA also maintains the viral episome and prevents Fas-induced programmed cell death.<xref ref-type="bibr" rid="article-23842.r19">[19]</xref>&#x000a0;NF-kB is activated by HHV-8 and up-regulates cytokine expression. Up-regulation of VEGF and bFGF results in neo-angiogenesis <xref ref-type="bibr" rid="article-23842.r19">[19]</xref>. It induces c-kit expression and produces the spindled morphology of Kaposi sarcoma cells from their original cuboidal monolayer.<xref ref-type="bibr" rid="article-23842.r19">[19]</xref>&#x000a0;Matrix metalloproteinases are upregulated by HHV-8.<xref ref-type="bibr" rid="article-23842.r19">[19]</xref></p>
        <p>Interestingly, Kaposi sarcoma is not monoclonal and different nodules within a patient have different clonal origins.<xref ref-type="bibr" rid="article-23842.r14">[14]</xref></p>
        <p>Clinically, Kaposi sarcoma is a vascular lesion, and as such,&#x000a0;often presents as a violaceous pink to purple plaque on the skin or mucocutaneous surfaces. Lesions may be painful with associated lymphedema and secondary infection.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref><xref ref-type="bibr" rid="article-23842.r19">[19]</xref>&#x000a0;There are 3 major stages on the skin: patch, plaque, and nodule.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref>&#x000a0;Lesions may ulcerate or invade into nearby tissues.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref>&#x000a0;In addition to involving lymph nodes, Kaposi sarcoma has a predilection for the lungs and gastrointestinal system, but can also occur in other visceral organs.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref>&#x000a0;Respiratory involvement can be associated with death due Kaposi sarcoma.<xref ref-type="bibr" rid="article-23842.r19">[19]</xref></p>
      </sec>
      <sec id="article-23842.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Kaposi sarcoma progresses through 3 distinct clinical stages: patch, plaque, and nodular.</p>
        <p>The patch stage of Kaposi sarcoma is characterized by a spindle cell proliferation of irregular, complex vascular channels dissecting through the dermis with the promontory sign, defined as ramifying proliferating vessels surrounding larger ectatic pre-existing vessels and skin adnexa.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref><xref ref-type="bibr" rid="article-23842.r3">[3]</xref>&#x000a0;Extravasated red blood cells, hemosiderin-laden macrophages, rare hyaline globules, and perivascular lymphocytes and plasma cells are also frequently identified.</p>
        <p>Advancement to the plaque stage of Kaposi sarcoma has an increasing prominence of the features seen in the patch stage with extension into the subcutis, and more prominence of the hyaline globules intra- and extra-cellularly.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref><xref ref-type="bibr" rid="article-23842.r3">[3]</xref>&#x000a0;These hyaline globules are periodic acid-Schiff positive and demonstrate Weibel-Palade bodies by electron microscopy.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref>&#x000a0;Cellular pleomorphism is minimal, and there are few mitotic figures.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref><xref ref-type="bibr" rid="article-23842.r3">[3]</xref></p>
        <p>As Kaposi sarcoma develops into the nodular form, the pleomorphism increases and mitotic figures become more prominent <xref ref-type="bibr" rid="article-23842.r3">[3]</xref>. The slit-like lumens&#x000a0;are enhanced&#x000a0;as&#x000a0;well.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref><xref ref-type="bibr" rid="article-23842.r3">[3]</xref></p>
        <p>Histologic variants of Kaposi sarcoma include: in situ Kaposi sarcoma, anaplastic Kaposi sarcoma, lymphangiectatic Kaposi sarcoma, bullous Kaposi sarcoma, ecchymotic Kaposi sarcoma, glomeruloid Kaposi sarcoma, and hyperkeratotic Kaposi sarcoma.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref></p>
        <p>The&#x000a0;presence of HHV-8 can be confirmed with immunohistochemistry for LANA1.<xref ref-type="bibr" rid="article-23842.r14">[14]</xref></p>
      </sec>
      <sec id="article-23842.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A general history and physical are performed first. The skin is examined for purplish lesions or lymph node enlargement that may signal the presence of&#x000a0;Kaposi sarcoma. Suspicious lesions on the skin or lymph nodes can be biopsied and sent to pathology for evaluation. Particular&#x000a0;care and attention should be paid to mucocutaneous surfaces as it is a common presenting location.</p>
      </sec>
      <sec id="article-23842.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>For a definitive diagnosis of Kaposi sarcoma, they must perform a biopsy or excision of the suspicious areas. A pathologist examines the tissue under the microscope and looks for the characteristic features: a spindle cell vascular proliferation in the dermis.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref><xref ref-type="bibr" rid="article-23842.r3">[3]</xref>&#x000a0;Immunohistochemistry positivity for LANA1 (a surrogate marker for HHV-8) helps to differentiate Kaposi sarcoma from similar lesions. The lesional cells also express CD34, factor VIII, PECAM-1, D2-40, VEGFR-3, and BCL-2.<xref ref-type="bibr" rid="article-23842.r20">[20]</xref></p>
      </sec>
      <sec id="article-23842.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Skin involvement of Kaposi sarcoma is treated by local excision, liquid nitrogen, and injection of vincristine.<xref ref-type="bibr" rid="article-23842.r19">[19]</xref><xref ref-type="bibr" rid="article-23842.r6">[6]</xref>&#x000a0;Chemotherapy is a mainstay of treatment for endemic and systemic forms, in particular in children.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref><xref ref-type="bibr" rid="article-23842.r9">[9]</xref></p>
        <p>Patients with HIV-related Kaposi sarcoma respond well to HAART,<xref ref-type="bibr" rid="article-23842.r21">[21]</xref><xref ref-type="bibr" rid="article-23842.r22">[22]</xref>&#x000a0;which can cause regression or complete treatment of their sarcoma. In patients with severe Kaposi sarcoma, combines HAART with chemotherapy.<xref ref-type="bibr" rid="article-23842.r23">[23]</xref>&#x000a0;Iatrogenic Kaposi sarcoma treatment must balance a reduction in immune suppression or withdrawal of steroid treatment with transplant rejection and treatment of the sarcoma.<xref ref-type="bibr" rid="article-23842.r9">[9]</xref></p>
      </sec>
      <sec id="article-23842.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Histologically, spindle cell vascular lesions in the skin include a differential diagnosis of<xref ref-type="bibr" rid="article-23842.r20">[20]</xref><xref ref-type="bibr" rid="article-23842.r3">[3]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Interstitial granuloma annulare</p>
          </list-item>
          <list-item>
            <p>Spindle cell hemangioma</p>
          </list-item>
          <list-item>
            <p>Acquired tufted angioma</p>
          </list-item>
          <list-item>
            <p>Kaposiform hemangioendothelioma</p>
          </list-item>
          <list-item>
            <p>Cutaneous angiosarcoma</p>
          </list-item>
          <list-item>
            <p>Fibrosarcomatous dermatofibrosarcoma protuberans</p>
          </list-item>
          <list-item>
            <p>Aneurysmal dermatofibroma</p>
          </list-item>
          <list-item>
            <p>Acroangiodermatitis</p>
          </list-item>
          <list-item>
            <p>Spindle cell melanoma</p>
          </list-item>
          <list-item>
            <p>High-grade sarcomas</p>
          </list-item>
        </list>
        <p>The differential diagnosis of Kaposi sarcoma on mucocutaneous surfaces includes<xref ref-type="bibr" rid="article-23842.r6">[6]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nevi</p>
          </list-item>
          <list-item>
            <p>Pyogenic granuloma</p>
          </list-item>
          <list-item>
            <p>Bacillary angiomatosis</p>
          </list-item>
          <list-item>
            <p>Hemangioma</p>
          </list-item>
          <list-item>
            <p>Angiosarcoma</p>
          </list-item>
          <list-item>
            <p>Melanoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23842.s11" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Classical Kaposi sarcoma tends to be radiosensitive, especially in early stages of the disease. Dosages recommended are 15.2 Gy for oral lesions, 20 Gy for conjunctiva, eyelids, lips, hands, feet, penis, and anal regions, and 30 Gy with hypofractionation&#x000a0;for other parts of the body.<xref ref-type="bibr" rid="article-23842.r21">[21]</xref>&#x000a0;For later stages of Kaposi sarcoma, radiation treatment may be used palliatively to reduce pain, edema, and bleeding.<xref ref-type="bibr" rid="article-23842.r21">[21]</xref></p>
      </sec>
      <sec id="article-23842.s12" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Thalidomide, VEGF inhibitors, tyrosine kinase inhibitors, and matrix metalloproteinases are currently&#x000a0;under investigation as single agents to treat Kaposi sarcoma.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref><xref ref-type="bibr" rid="article-23842.r24">[24]</xref>&#x000a0;Several studies are currently&#x000a0;ongoing for new and novel treatment for Kaposi sarcoma, including<xref ref-type="bibr" rid="article-23842.r25">[25]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intra-lesional nivolumab for cutaneous Kaposi sarcoma</p>
          </list-item>
          <list-item>
            <p>Pomalidomide with liposomal doxorubicin for refractory Kaposi sarcoma</p>
          </list-item>
          <list-item>
            <p>Pembrolizumab for relapsed and refractory HIV related neoplasms</p>
          </list-item>
          <list-item>
            <p>Ipilimumab and nivolumab for advanced HIV related neoplasms</p>
          </list-item>
          <list-item>
            <p>Nelfinavir for endemic, classic, and HIV-related Kaposi sarcoma</p>
          </list-item>
          <list-item>
            <p>Valganciclovir for HIV-related Kaposi sarcoma, particularly patients with immune reconstitution syndrome</p>
          </list-item>
          <list-item>
            <p>Recombinant EphB4-HAS fusion protein</p>
          </list-item>
          <list-item>
            <p>Selumetinib</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23842.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>High-activity antiretroviral therapy (HAART) is the mainstay of treatment in patients with AIDS-related Kaposi sarcoma. Not only does HAART treatment reduce the risk of development of Kaposi sarcoma, but it also can lead to spontaneous regression of the tumors.<xref ref-type="bibr" rid="article-23842.r21">[21]</xref><xref ref-type="bibr" rid="article-23842.r22">[22]</xref></p>
        <p>For local disease, sclerotherapy, intralesional vinca-alkaloids, bleomycin, interferon-alpha, topical alitretinoin, or imiquimod cream have all been used with success.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref></p>
        <p>Systemic chemotherapy approved for treatment of Kaposi sarcoma includes liposomal anthracyclins, paclitaxel, etoposide, vincristine, vinblastine, vinorelbine, bleomycin, or a combination of doxorubicin, bleomycin, and vincristine.<xref ref-type="bibr" rid="article-23842.r19">[19]</xref><xref ref-type="bibr" rid="article-23842.r6">[6]</xref>&#x000a0;Others have used interferon-alpha 2b with success.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref>&#x000a0;Other therapies tried to include thalidomide, VEGF inhibitors, tyrosine kinase inhibitors, and matrix metalloproteinases but further research into these as single agents is still being conducted.<xref ref-type="bibr" rid="article-23842.r6">[6]</xref><xref ref-type="bibr" rid="article-23842.r24">[24]</xref></p>
      </sec>
      <sec id="article-23842.s14" sec-type="Staging">
        <title>Staging</title>
        <p>Kaposi sarcoma is not usually staged, however, a staging system was initially developed in the 1980s for HIV-related Kaposi sarcoma by the AIDS Clinical Trials Group.<xref ref-type="bibr" rid="article-23842.r26">[26]</xref><xref ref-type="bibr" rid="article-23842.r13">[13]</xref>&#x000a0;With modern HAART, there are 2 proposed risk categories: good and poor.<xref ref-type="bibr" rid="article-23842.r26">[26]</xref>&#x000a0;Poor prognosis was based on poor tumor stage and poor systemic disease status.<xref ref-type="bibr" rid="article-23842.r26">[26]</xref></p>
      </sec>
      <sec id="article-23842.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Ten percent to 20% of patients with the classic form of Kaposi sarcoma will succumb from their disease, but another larger percentage will develop a secondary malignancy that may also be lethal.<xref ref-type="bibr" rid="article-23842.r3">[3]</xref>&#x000a0;Endemic, HIV-related, and iatrogenic forms of Kaposi sarcoma have a variable prognosis. Prognosis may depend on CD4 count and opportunistic infections. In patients with iatrogenic Kaposi sarcoma, the prognosis is dependent on their underlying condition and their ability to tolerate a reduction in immunosuppression.<xref ref-type="bibr" rid="article-23842.r3">[3]</xref>&#x000a0;Worse prognosis is usually found in patients with visceral organ involvement, particularly the lungs.<xref ref-type="bibr" rid="article-23842.r3">[3]</xref><xref ref-type="bibr" rid="article-23842.r19">[19]</xref></p>
      </sec>
      <sec id="article-23842.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Larger lesions can be painful and lead to edema and disfigurement of the skin. Pulmonary involvement of Kaposi sarcoma can cause respiratory distress and lead to death. Classic Kaposi sarcoma has a known association with the development of a secondary malignancy.</p>
        <p>Chemotherapy is not without side effects, including but not limited to neurotoxicity, infertility, cardiac toxicity, and nerve pain.</p>
        <p>Radiation therapy can lead to drying of the skin, avascularity, poor healing, development of additional malignancies, and lymphedema.</p>
      </sec>
      <sec id="article-23842.s17" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Patients should be followed closely for resolution or recurrence of their disease.</p>
      </sec>
      <sec id="article-23842.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="order">
          <list-item>
            <p>There are 4 major forms of Kaposi sarcoma: classic, endemic, HIV-related, and iatrogenic, each with a different patient population and presentation.</p>
          </list-item>
          <list-item>
            <p>All cases of Kaposi sarcoma harbor the HHV-8 virus, though this is not sufficient to cause the neoplasm.</p>
          </list-item>
          <list-item>
            <p>Histologically, Kaposi sarcoma presents as a spindle cell vascular neoplasm with extravasated red blood cells and hyaline globules.</p>
          </list-item>
          <list-item>
            <p>Immunohistochemistry for LANA-1 can confirm the presence of&#x000a0;HHV-8 in the neoplastic cells.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23842.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Kaposi sarcoma has been definitively linked to HHV-8 infection with increased incidence in patients with HIV infection, immunosuppression, or of Eastern European or Mediterranean descent. In seropositive patients at high risk of development of Kaposi sarcoma, the primary care team should take care to perform thorough skin exams looking for the characteristic violaceous patches and plaques. Additionally, patients in these high-risk groups should be counseled to examine their skin as well for lesions. Discovery of any suspicious lesions should prompt expedient biopsy and examination by a pathologist. Patient care is enhanced by the submitting provider providing a complete clinical history and mentioning the suspicion for Kaposi sarcoma to the reviewing pathologist.</p>
        <p>Patients who are diagnosed with Kaposi sarcoma should be closely monitored for disease regression or recurrence and need for radiation treatment or systemic chemotherapy. If the HIV-associated or iatrogenic form, the clinical team should communicate and work closely to begin HAART or help reduce the immunosuppression while treating the patients underlying condition. (Level I)</p>
        <p>Dentists and oral health care providers should be educated about the clinical presentation in the oral cavity as this a common location.</p>
      </sec>
      <sec id="article-23842.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23842&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23842">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/kaposi-sarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23842">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23842/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23842">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23842.s21">
        <fig id="article-23842.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Kaposi Sarcoma <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kaposiSarcoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23842.s22">
        <fig id="article-23842.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Histopathology of Kaposi sarcoma Contributed by Bradie Bishop, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="KaposiSarcoma1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-23842.s23">
        <fig id="article-23842.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Kaposi sarcoma Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="kaposi__mouth" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23842.s24">
        <title>References</title>
        <ref id="article-23842.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St&#x00103;nescu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Foarf&#x00103;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Georgescu</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Georgescu</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's sarcoma associated with AIDS.</article-title>
            <source>Rom J Morphol Embryol</source>
            <year>2007</year>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-7</page-range>
            <pub-id pub-id-type="pmid">17641807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flore</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rafii</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ely</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hyjek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cesarman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.</article-title>
            <source>Nature</source>
            <year>1998</year>
            <month>Aug</month>
            <day>06</day>
            <volume>394</volume>
            <issue>6693</issue>
            <fpage>588</fpage>
            <page-range>588-92</page-range>
            <pub-id pub-id-type="pmid">9707121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maru&#x00161;i&#x00107;</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Billings</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of Spindle Cell Vascular Tumors.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-366</page-range>
            <pub-id pub-id-type="pmid">28477885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kem&#x000e9;ny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gyulai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dobozy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8: a new virus in human pathology.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-13</page-range>
            <pub-id pub-id-type="pmid">9216532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bisceglia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Minenna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Altobella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanguedolce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panniello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bisceglia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ben-Dor</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Anaplastic Kaposi's Sarcoma of the Adrenal in an HIV-negative Patient With Literature Review.</article-title>
            <source>Adv Anat Pathol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-149</page-range>
            <pub-id pub-id-type="pmid">30212382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fatahzadeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma: review and medical management update.</article-title>
            <source>Oral Surg Oral Med Oral Pathol Oral Radiol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-16</page-range>
            <pub-id pub-id-type="pmid">22677687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iscovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boffetta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Franceschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarid</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Classic kaposi sarcoma: epidemiology and risk factors.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Feb</month>
            <day>01</day>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>500</fpage>
            <page-range>500-17</page-range>
            <pub-id pub-id-type="pmid">10649240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gotuzzo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease.</article-title>
            <source>Int J Infect Dis</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>239</fpage>
            <page-range>239-50</page-range>
            <pub-id pub-id-type="pmid">16095940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Dittmer</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Kaposi Sarcoma.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-539</page-range>
            <pub-id pub-id-type="pmid">28324233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Etta</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Alayande</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Mavhandu-Ramarumo</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Gachara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bessong</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>HHV-8 Seroprevalence and Genotype Distribution in Africa, 1998&#x0207b;2017: A Systematic Review.</article-title>
            <source>Viruses</source>
            <year>2018</year>
            <month>Aug</month>
            <day>27</day>
            <volume>10</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">30150604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dedicoat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma.</article-title>
            <source>Br J Cancer</source>
            <year>2003</year>
            <month>Jan</month>
            <day>13</day>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-3</page-range>
            <pub-id pub-id-type="pmid">12556950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatlynne</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Ablashi</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV).</article-title>
            <source>Semin Cancer Biol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-85</page-range>
            <pub-id pub-id-type="pmid">10343069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yarchoan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uldrick</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>HIV-Associated Cancers and Related Diseases.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>378</volume>
            <issue>11</issue>
            <fpage>1029</fpage>
            <page-range>1029-1041</page-range>
            <pub-id pub-id-type="pmid">29539283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mariggi&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma herpesvirus pathogenesis.</article-title>
            <source>Philos Trans R Soc Lond B Biol Sci</source>
            <year>2017</year>
            <month>Oct</month>
            <day>19</day>
            <volume>372</volume>
            <issue>1732</issue>
            <pub-id pub-id-type="pmid">28893942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tounouga</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Kouotou</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Nansseu</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Zoung-Kanyi Bissek</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological and Clinical Patterns of Kaposi Sarcoma: A 16-Year Retrospective Cross-Sectional Study from Yaound&#x000e9;, Cameroon.</article-title>
            <source>Dermatology</source>
            <year>2018</year>
            <volume>234</volume>
            <issue>5-6</issue>
            <fpage>198</fpage>
            <page-range>198-204</page-range>
            <pub-id pub-id-type="pmid">30205412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemlich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schwam</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2 Pt 1</issue>
            <fpage>319</fpage>
            <page-range>319-25</page-range>
            <pub-id pub-id-type="pmid">3029191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Paya</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Kaposi's Sarcoma and Transplantation.</article-title>
            <source>Herpes</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-23</page-range>
            <pub-id pub-id-type="pmid">11866996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luppi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barozzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rasini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Torelli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>HHV-8 infection in the transplantation setting: a concern only for solid organ transplant patients?</article-title>
            <source>Leuk Lymphoma</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>517</fpage>
            <page-range>517-22</page-range>
            <pub-id pub-id-type="pmid">12002754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>103</fpage>
            <page-range>103-8</page-range>
            <pub-id pub-id-type="pmid">24319170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pantanowitz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>137</volume>
            <issue>2</issue>
            <fpage>289</fpage>
            <page-range>289-94</page-range>
            <pub-id pub-id-type="pmid">23368874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Temelkova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tronnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terziev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wollina</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lozev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goldust</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tchernev</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Series of Patients with Kaposi Sarcoma (Mediterranean/Classical Type): Case Presentations and Short Update on Pathogenesis and Treatment.</article-title>
            <source>Open Access Maced J Med Sci</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>1688</fpage>
            <page-range>1688-1693</page-range>
            <pub-id pub-id-type="pmid">30337990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cattelan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Trevenzoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aversa</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in the treatment of AIDS-related Kaposi's sarcoma.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2002</year>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>451</fpage>
            <page-range>451-62</page-range>
            <pub-id pub-id-type="pmid">12180893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gbabe</surname>
                <given-names>OF</given-names>
              </name>
              <name>
                <surname>Okwundu</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Dedicoat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <issue>9</issue>
            <fpage>CD003256</fpage>
            <pub-id pub-id-type="pmid">25313415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dittmer</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Damania</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.</article-title>
            <source>J Clin Invest</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>126</volume>
            <issue>9</issue>
            <fpage>3165</fpage>
            <page-range>3165-75</page-range>
            <pub-id pub-id-type="pmid">27584730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bender Ignacio</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Rajdev</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chiao</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1018</fpage>
            <page-range>1018-1026</page-range>
            <pub-id pub-id-type="pmid">30099376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23842.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Talamini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Antinori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martellotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jacchetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chiodo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ballardini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stoppini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di Perri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tavio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaccher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D'Arminio Monforte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tirelli</surname>
                <given-names>U</given-names>
              </name>
              <collab>AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive from Antiretrovirals</collab>
            </person-group>
            <article-title>AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Aug</month>
            <day>01</day>
            <volume>21</volume>
            <issue>15</issue>
            <fpage>2876</fpage>
            <page-range>2876-82</page-range>
            <pub-id pub-id-type="pmid">12885804</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
